Recently, there has been considerable interest in a possible link between changes in brain polyunsaturated fatty acids, neural membrane phospholipid degradation, serotonergic neurotransmission, and depression. The present study aims to examine effects of antidepressants on lipids in different regions of the brain at individual molecular species level, using the novel technique of lipidomics. Balb/C mice received daily intraperitoneal (i.p.) injections of 10 mg/kg of the antidepressants maprotiline, fluoxetine and paroxetine for 4 wk. The prefrontal cortex, hippocampus, striatum and cerebellum were harvested, and lipid profiles compared to those of saline-injected mice. Treatment with maprotiline and paroxetine, but not fluoxetine, resulted in significant decreases in phosphatidylcholine (PC) species, PC36:1, PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p and PC42:5p in the prefrontal neocortex. The decreases in phospholipids were accompanied by increases in lysophospholipid species, lysoPC16:0, lysoPC18:2 and lysoPC18:0 in the prefrontal cortex, indicating increase in phospholipase A 2 activity and possible release of long-chain fatty acids. Maprotiline and paroxetine treatment also resulted in decreases in sphingomyelin and increases in several ceramide species in the prefrontal cortex. It is postulated that endogenous release of long-chain fatty acids may be related to the mechanism of action of maprotiline and paroxetine.
Introduction
Depression, a potentially life-threatening disease, is a major public health problem. About 13-20 % of the world's population has some depressive symptoms at any given time and about 5 % of the population is estimated to suffer from major depression. Neuroimaging and post-mortem studies have identified abnormalities in brain areas such as the prefrontal cortex and limbic system in subjects with major depression (Botteron et al. 2002 ; Drevets, 2000 Drevets, , 2003 . Many antidepressant medications work by interacting with serotonin or noradrenaline uptake, thus increasing synaptic levels of monoamine neurotransmitters and inducing changes in signal transduction cascades (Coyle & Duman, 2003 ; Donati & Rasenick, 2003) . Elevations of neurotransmitter levels in the brain are almost instantaneous but elevation of mood is delayed until at least 2 wk later (Katz et al. 2004 ; Mitchell, 2006) .
Recently, there has been considerable interest in a possible link between changes in brain polyunsaturated fatty acids, neural membrane phospholipid degradation, serotonergic neurotransmission, and depression (Maes et al. 1999) . Low levels of omega-3 fatty-acid intake may be associated with depression and alterations in serotonergic function (Hibbeln, 1998 ; Logan, 2003 Logan, , 2004 Mischoulon & Fava, 2000 ; Peet et al. 1998 ; Su et al. 2003 Su et al. , 2008 . Seasonal (De Vriese et al. 2004 ) and geographic (Hibbeln, 1998) variations in intake of omega-3 fatty acids are also linked to the incidence of depression. Conversely, intake of high levels of omega-3 fatty acids has been reported to have an antidepressant effect (Logan, 2003 (Logan, , 2004 Mischoulon & Fava, 2000 ; Su et al. 2003 Su et al. , 2008 . It is proposed that some of these processes may be involved in the action of antidepressant drugs . The balance between omega-3 and omega-6 acids allows neural cell membranes to develop with exactly the right flexibility and fluidity to carry messages among neurons and glial cells (Caramia, 2008) .
Many antidepressants are cationic amphiphilic drugs that interact with the lipid bilayer (Fisar et al. 2004 ; Herbette et al. 1986 ; Seydel et al. 1994) . Highaffinity binding of tricyclic antidepressants to phosphatidylcholine (PC) or phosphatidylethanolamine (PE) has been demonstrated (Fisar, 2005) . PC and PE are two of the most abundant phospholipids and they play an important role in maintaining membrane integrity as well as generating downstream signal transduction (Exton, 1994 ; Fisk & Kano-Sueoka, 1992) . However, thus far, little is known about the effects of antidepressants on lipids in different regions of the brain, at individual molecular species level.
Lipidomics is a systems-level analysis and characterization of lipids and their interacting moieties (Adibhatla et al. 2006 ; Wenk, 2005) . Tandem mass spectrometry analysis (MS/MS) together with multiple reaction monitoring (MRM) is used for quantitative analysis of lipids with known fragmentation profiles with up-front liquid chromatography (Watson, 2006) . In view of the above-mentioned studies showing lipid changes in depressed subjects/animals, as well as after antidepressant treatment, we hypothesize that specific lipid species might be altered after chronic antidepressant treatment. The present study aims to examine changes in lipid profiles in various regions of the mouse brain through lipidomics, using three different antidepressants of two main pharmacological classes, maprotiline (selective noradrenaline reuptake inhibitor ; SNRI), fluoxetine, and paroxetine (selective serotonin reuptake inhibitors ; SSRIs).
Methods

Antidepressant treatment and collection of brain tissues
Sixteen male Balb/C mice weighing 20-30 g each and aged y6-8 wk were used for this study. They were housed under defined conditions (room temperature 22 xC, relative humidity 65 %, 12-h light/dark cycle, lights on 07:00 hours) with free access to food and water. The mice were divided into four equal groups, and given daily intraperitoneal (i.p.) injections of maprotiline, fluoxetine or paroxetine (Sigma-Aldrich Co., USA, 10 mg/kg in saline) or saline for 4-wk duration. The dose of 10 mg/kg of was chosen based on previous studies which showed behavioural changes in animal models (Parra et al. 2000 ; Pinhasov et al. 2005 ; Reneric et al. 2001 ; Shirayama et al. 2002) as well as neurochemical changes (Alme et al. 2007 ; Laakso et al. 1996 ; Martinez-Turrillas et al. 2002 ; Tan et al. 2006) after antidepressant administration. This duration is also sufficient for antidepressants to exert their therapeutic effects in relation to adaptive cellular changes (Fisar, 2005) . The mice were sacrificed after 4 wk of treatment. They were deeply anaesthetized by i.p. injection of a ketamine/xylazine cocktail, followed by decapitation. The left and right prefrontal cortex, hippocampus, striatum and cerebellum were rapidly collected, snap-frozen in liquid nitrogen and stored at x80 xC until required. All procedures involving animals were in accordance with guidelines of the Institutional Animal Care and Use Committee.
Lipid extraction
A widely used modified protocol of Bligh and Dyer was used (Bligh & Dyer, 1959) . Tissues were homogenized in 750 ml chloroform-methanol, 1 : 2 (v/v) using Tissue Tearor TM (Biospec Inc., USA). Samples were vortexed and incubated on ice for 15 min with vortexing performed at each 5-min interval. Subsequently, 250 ml chloroform and 450 ml of 0.88 % potassium chloride (KCl) were added. Samples were vortexed and incubated on ice for 1 min. Lipids were isolated from the organic phase after centrifugation (9000 rpm, 4 xC, 2 min). Samples were then vacuumdried (Thermo Savant SpeedVac, USA), resuspended in chloroform-methanol (1 : 1 v/v), and used for analysis.
Analysis of lipids using high-performance liquid chromatography/mass spectrometry (HPLC/MS) An Agilent HPLC system coupled with a Triple Quadrupole/Ion Trap mass spectrometer (4000 Q trap, Applied Biosystems, USA) was used for quantification of individual polar lipids. Samples were introduced into the mass spectrometer by loop injections with chloroform : methanol (1 : 1) as a mobile phase for positive electrospray ionization (ESI) mode and chloroform : methanol : 200 mM piperidine (1 : 1 : 0.1) as a mobile phase for negative ESI mode, respectively, both at a flow of 250 ml/min (Shui et al. 2007) . Based on product ion and precursor ion analyses of head groups, two comprehensive sets of MRM transitions were set up for quantitative analysis of various lipids including PCs, PEs, phosphatidylserines (PSs), phosphatidylinositols (PIs), phosphatidylglycerols (PGs), phosphatidic acids (PAs), sphingomyelins (SMs) and ceramides (Cers) (Fei et al. 2008) . The signal intensity of each MRM value was normalized using equation (1). 
Statistical analysis
The data were analysed using SPSS statistical software version 16.0 (SPSS Inc., USA). Shapiro-Wilk values showed that the data were normally distributed.
Comparisons of the means of various lipids were performed for the control and treatment groups. The differences between control and treatment groups were determined statistically using Student's t test [using false discovery rate (FDR) adjustment] with the assumption of unequal variances. FDR <0.05 was considered statistically significant.
Results
Overall changes in relative abundances of most lipid species analysed in the various brain regions are displayed as heat plots using their normalized intensity. The ' raw data heat plots' show that there are no gross perturbations in lipids after antidepressant treatment (Figs 1 and 2 ). In comparison, ' ratio heat plots ' (where relative abundance of saline is fixed as a value of 1) show clearer changes in lipid even with low relative abundances (Figs 3 and 4) .
Prefrontal cortex ( Table 1 , Figs 1 a, 3 a)
Maprotiline
There was a significant reduction in relative abundance of PC species (PC36:1, PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p, PC42:5p) and significant increase in relative abundance of PC30:0e, PC30:0, PC32:0 and PC36:3p in the cortex of the maprotilinetreated mice, compared to controls. In contrast to the decrease in PCs, an increase in relative abundance of lysophosphatidylcholine species, lysoPC16:1, lysoPC16:0, lysoPC18:2, lysoPC18:1, lysoPC18:0 and lysoPC20:4 was detected after maprotiline treatment. PE species, PE34:2, PE36p:4, PE36:5 and PE40p:4 were decreased after treatment. SM species, SM18/16:0 was increased, whilst SM18/24:1 and SM18/24:0 were decreased after treatment. Cer species, Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/20:0, Cer d18:1/22:0 and Cer d18:1/24:0 showed significant increase after treatment. PI38:6 and PI40:4 were significantly increased.
Fluoxetine
There was a non-significant trend for a reduction in relative abundance of PCs in the cortex of mice treated with fluoxetine. A non-significant trend for an increase in relative abundance of lysoPCs was also detected.
Paroxetine
There was a significant reduction in relative abundance of PC36:3, PC36:1, PC38:4, PC38:3, PC40:2p, PC40:1p, PC40:6, PC40:5, PC42:7p, PC42:6p, PC42:5p and significant increase in relative abundance of PC32:0 and PC38:6 in the cortex of paroxetine-treated mice, compared to controls. In contrast to the decrease in PCs, an increase in relative abundance of lysoPC species including lysoPC16:0, lysoPC18:2 and lysoPC18:0 was detected after treatment. PE36p:4, PE36:5, PE38:5 and SM18/24:1, SM18/24:0 showed significant decrease, whilst Cer species, Cer d18:1/18:0, Cer d18:1/ 20:0, Cer d18:1/22:0 and Cer d18:1/24:1 showed significant increase after treatment. PI38:6 and PI40:6 were significantly increased.
Hippocampus (Table 2 
Maprotiline
There were no significant changes in any of the lipids analysed in the hippocampus of maprotiline-treated mice. 
Fluoxetine
There were no significant changes in any of the lipids analysed in the hippocampus of fluoxetine-treated mice.
Paroxetine
There were no significant changes in any of the lipids analysed in the hippocampus of paroxetine-treated mice except lysoPC18:1, which showed a significant decrease in relative abundance after treatment.
Striatum (Table 3, Figs 2 a, 4 a)
There were no significant changes in any of the lipids analysed in the striatum of mice treated with antidepressants.
Cerebellum (Table 4 There were no significant changes in any of the lipids analysed in the cerebellum of mice treated with antidepressants.
Discussion
The present study was performed in order to elucidate possible effects of SNRI and SSRI antidepressant drugs on brain lipid profiles. Decreases in PC species, PC36:1, PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p and PC42:5p were detected in the prefrontal cortex after treatment with two out of the three antidepressants (maprotiline and paroxetine). Fluoxetine showed similar trends in the cortex as the other two antidepressants used, although the results were not statistically significant. The striatum exhibited a general reduction in PE species, although the results were not statistically significant. The decrease in PC species in the prefrontal cortex was accompanied by changes in lysoPC species in the same brain region. These included increases in lysoPC16:0, lysoPC18:2 and lysoPC18:0 in the prefrontal cortex after treatment with maprotiline and paroxetine. Relatively little change in lipids was observed in the striatum, hippocampus and cerebellum, compared to the prefrontal cortex. LysoPCs are able to exert their effects by affecting membrane permeability and fluidity along with a variety of biological effects (Farooqui et al. 1997) . They also participate in many signal transduction processes ; modulate ion channel permeability, cell-cell and membrane-membrane interactions and neurotransmitter release (Farooqui et al. 2008) . PC is one of the major phospholipids found distributed in membrane bilayers (Devaux, 1991) . The decrease in phospholipids and increases in the corresponding lysophospholipids in the cortex suggest the action of phospholipase A 2 (PLA 2 ) activity after antidepressant treatment. PLA 2 is a lipolytic enzyme that hydrolyses the acyl group at the sn-2 position of membrane phospholipids to produce free fatty acids and lysophospholipids (Farooqui & Horrocks, 2004) . Based on the decrease in PC species (PC36:1, PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p and PC42:5p) but increases in lysophospholipid species, i.e. lysoPC16:0, lysoPC18:2 and lysoPC18:0 in the prefrontal cortex of the antidepressant treated mice, we can deduce the identity of the fatty-acid side-chain being released. For instance, PC40:6 -lysoPC18:0=22:6 docosahexaenoic acid (DHA). In addition to DHA, it is possible that even longer-chain fatty acids, such as tetracosapentaenoic acid (24:5 ; e.g. PC42:5p -lysoPC18:0 or PC40:5 -lysoPC 16:0) or tetracosahexaenoic acid (nisinic acid) (24:6) may also be released through the action of antidepressants. Omega-3 and omega-6 long-chain polyunsaturated fatty acids are major structural components of neuronal and glial cell membranes, and changing the fatty-acid composition of neuronal membrane during depression may lead to functional changes in the activity of receptors, ion channels, and other proteins embedded in membrane phospholipids (Farooqui & Horrocks, 2007) . Changes in polyunsaturated fatty-acid levels may modulate lipid/lipid raft composition, a process that affects G-protein receptor-mediated monoamine signalling (Tyeryar et al. 2008) . This signalling may promote synaptic plasticity, neurogenesis, and adaptation associated with action of antidepressants (Warner-Schmidt & Duman, 2006) . Decreases in SM species, SM18/24:1 and SM18/24:0 and increases in Cer species, Cer d18:1/18:0, Cer d18:1/20:0 and Cer d18:1/22:0 were also detected after maprotiline and paroxetine treatment, possibly due to sphingomyelinase activity.
In contrast to maprotiline and paroxetine, which produce changes in PCs, lysoPCs, SMs and Cers, no significant changes in lipids were found after treatment with fluoxetine. In-vitro studies show that 5-HT 2 receptors are coupled via G proteins to PLA 2 activation (Axelrod, 1990 ; Felder et al. 1990 ; Qu et al. 2003) and it has been reported that fluoxetine treatment results in an increase in cytosolic PLA 2 enzyme protein levels and activity in the rat brain (Rao et al. 2006) . However, our results are in contrast to these results and showed no significant changes in lipids after treatment with fluoxetine. This is in contrast to paroxetine, which has a similar mechanism of action. The reason for this is unknown but indicates that inducing changes in lipids cannot be the only mechanism for the action of antidepressants.
We conclude that treatment with maprotiline and paroxetine results in changes in PCs, lysoPCs, SMs, and Cers, and further studies are necessary to determine if these changes might related to the antidepressant action of these drugs. 
